Yong Sung Park

Yong Sung Park

Auto-generated profile, based on publicly available information

Yong Sung Park

Texas A&M Health Science Center 3 High-Throughput Research and Screening Center, Center for Translational Cancer Research Institute of Biosciences and Technology, Houston, Texas

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
Susmita GhoshSusmita Ghosh
Susmita Ghosh
FFFan Fan
Fan Fan
RPReid T. Powell
Reid T. Powell
Jason RoszikJason Roszik
Jason Roszik
YPYong Sung Park
Yong Sung Park
Rajat BhattacharyaRajat Bhattacharya
Rajat Bhattacharya
Mutations in KRAS are found in more than 50% of tumors from patients with metastatic colorectal cancer (mCRC). However, direct targeting of most KRAS mutations is difficult; even the recently developed KRASG12C inhibitors failed to show significant benefit in patients with mCRC. Single agents targeting mitogen-activated protein kinase kinase (MEK), a downstream mediator of RAS, have also been ineffective in colorectal cancer. To identify drugs that can enhance the efficacy of MEK inhibitors, we performed unbiased high-throughput screening using colorectal cancer spheroids. We used trametinib as the anchor drug and examined combinations of trametinib with the NCI-approved Oncology Library version 5. The initial screen, and following focused validation screens, identified vincristine as being strongly synergistic with trametinib. In vitro, the combination strongly inhibited cell growth, reduced clonogenic survival, and enhanced apoptosis compared with monotherapies in multiple KRAS-mutant colorectal cancer cell lines. Furthermore, this combination significantly inhibited tumor growth, reduced cell proliferation, and increased apoptosis in multiple KRAS-mutant patient-derived xenograft mouse models. In vivo studies using drug doses that reflect clinically achievable doses demonstrated that the combination was well tolerated by mice. We further determined that the mechanism underlying the synergistic effect of the combination was due to enhanced intracellular accumulation of vincristine associated with MEK inhibition. The combination also significantly decreased p-mTOR levels in vitro, indicating that it inhibits both RAS-RAF-MEK and PI3K-AKT-mTOR survival pathways. Our data thus provide strong evidence that the combination of trametinib and vincristine represents a novel therapeutic option to be studied in clinical trials for patients with KRAS-mutant mCRC. Significance: Our unbiased preclinical studies have identified vincristine as an effective combination partner for the MEK inhibitor trametinib and provide a novel therapeutic option to be studied in patients with KRAS-mutant colorectal cancer.

17 June 2026
Verified
Other
Open access
HBHannah Beird
Hannah Beird
CHCarl Ho
Carl Ho
RCRoberto Cardenas-Zuniga
Roberto Cardenas-Zuniga
AAAsmaa Ahmed
Asmaa Ahmed
CAClement Agyemang
Clement Agyemang
AFAndrew Futreal
Andrew Futreal
Figure S1. Unsupervised hierarchical clustering of drug AUC values after filtering for min = 0.2 (blue) and max = 0.7 (red).

17 June 2026
Verified
Other
Open access
HBHannah Beird
Hannah Beird
CHCarl Ho
Carl Ho
RCRoberto Cardenas-Zuniga
Roberto Cardenas-Zuniga
AAAsmaa Ahmed
Asmaa Ahmed
CAClement Agyemang
Clement Agyemang
AFAndrew Futreal
Andrew Futreal
Table S2. Top 30 ranking sensitive compound for each cell line

17 June 2026
Verified
Other
Open access
HBHannah Beird
Hannah Beird
CHCarl Ho
Carl Ho
RCRoberto Cardenas-Zuniga
Roberto Cardenas-Zuniga
AAAsmaa Ahmed
Asmaa Ahmed
CAClement Agyemang
Clement Agyemang
AFAndrew Futreal
Andrew Futreal
Many of the >130 World Health Organization–defined sarcoma subtypes are chemoresistant. To identify drug candidates with potential for repurposing in sarcomas with unmet needs, we screened structurally diverse small molecules across 20 sarcoma cell lines of various histologies. The screen included 1,387 compounds from the Custom Clinical Collection, NCI-Approved Oncology Set IV, and Selleck Bioactive Collection. The most effective agents were microtubule inhibitors, aurora kinase inhibitors, and heat shock protein inhibitors. Differential drug sensitivity was observed by sarcoma subtype. Ewing sarcoma, for example, was sensitive to aurora kinases and to TORIN-2 (an mTOR inhibitor). In contrast, myxoid liposarcoma and synovial sarcomas exhibited marked sensitivity to SNS-032, a CDK2/7/9 inhibitor identified by our screen. Interestingly, SNS-032 abrogates the downstream YAP pathway, a known driver pathway in the growth of these histotypes. Therefore, similar drug responses across histologies may indicate shared driver pathways and vulnerabilities.Significance:Sarcoma cells are resistant to most compounds that are currently approved for treating various diseases. Ewing sarcoma cells have distinct sensitivities to aurora kinases that can be explored, whereas myxoid liposarcoma and synovial sarcoma cells share similar drug sensitivity fingerprints that could be exploited in future basket trials.

27 November 2025
Verified
Other
Open access
PDF file
Susmita GhoshSusmita Ghosh
Susmita Ghosh
FFFan Fan
Fan Fan
RPReid T. Powell
Reid T. Powell
Jason RoszikJason Roszik
Jason Roszik
YPYong Sung Park
Yong Sung Park
Rajat BhattacharyaRajat Bhattacharya
Rajat Bhattacharya
Supplementary Figure 5 shows that trametinib increases the intracellular accumulation of daunorubicin in KRAS-mutant CRC cells.

27 November 2025
Verified
Other
Open access
PDF file
Susmita GhoshSusmita Ghosh
Susmita Ghosh
FFFan Fan
Fan Fan
RPReid T. Powell
Reid T. Powell
Jason RoszikJason Roszik
Jason Roszik
YPYong Sung Park
Yong Sung Park
Rajat BhattacharyaRajat Bhattacharya
Rajat Bhattacharya
Supplementary Figure 6 shows that vinorelbine is also synergistic with trametinib in KRAS-mutant CRC 3D spheroids